Observational study of the persistence antiglaucoma eyedrops to

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (S01EA) Sympathomimetics in glaucoma therapy

  (S01EB) Parasympathomimetics

  (S01EC) Carbonic anhydrase inhibitors

  (S01ED) Beta blocking agents

  (S01EE01) latanoprost

  (S01EE03) bimatoprost

  (S01EE04) travoprost

  (S01EX) Other antiglaucoma preparations
• Medical condition to be studied:
  Glaucoma

Population studied

• Short description of the study population:
  French glaucoma patients treated with different topical ocular hypotensive medications identified from French national health insurance database (EGB).
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Glaucoma patients
• Estimated number of subjects:
  5000

Study design details

• Main study objective:
  To compare the 12-month persistence under different topical ocular hypotensive medications in glaucoma management.
• Outcomes:
  To define the prevalence and annual incidence of different types of antiglaucoma eyedrops and their respective changes between 2005 and 2010, To study and compare the persistence to 12 months of anti-glaucoma eye drops between major therapeutic classes in France between 2005 and 2010.To study the predictors of persistence for different types of antiglaucoma antiglaucoma eyedrops.
• Data analysis plan:
  A/ Study of the annual prevalence successively from 2004 to 2009,B/ Study the annual incidence successively from 2005 to 2009)C/ Description of the general characteristics of the study population at baselineD/ Description of antiglaucoma eyedrops initiated at T0E/ Description of characteristics related to the initiation of a given classF/ Description and comparison of the persistence rate at 12 months, and identification of factors associated with non-persistenceF-a/ According to the persistent / non-persistent status (binary approach)F-b/ Depending on the time of occurrence of the interruption (survival analysis)G/ Description of coverage in the first 12 months

Documents

Study publications

Belhassen M, Laforest L, Licaj I, Van Ganse E. Early adherence to anti-glaucoma…